While these areas are confirmed as pillars of national sovereignty, Washington’s economic, commercial and financial blockade hinders their progress, the Cuban mission said in a press release.
“Such repercussions are evident in the BioCubaFarma business group, in charge of producing medicines, equipment and high-tech services for the improvement of human health, the generation of goods and services for export and the production of food with cutting-edge technology.”
The effect of the blockade on Cuba’s biotechnological and pharmaceutical industry not only affects its inhabitants, but also deprives US citizens, among others, of receiving the benefits of biotechnological and pharmaceutical products developed in Cuba, the press release pointed out.
In this regard, it referred to Cuban medicines of international recognition, such as HEBERPROT-P, GAVAC or Proctokinase, which cannot be exported to the United States due to the restrictions imposed by the economic, commercial and financial blockade.
According to Cuba’s mission at the UN, the fact that these products cannot enter the US market has cost the Center for Genetic Engineering and Biotechnology (CIGB) millions of dollars in losses regarding income from the non-export of goods and services.